Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001

Medical Mycology

Volumn 41, Issue 6, 2003, Pages 521-528

  Ellis, Michael ^a,b   Hedstrom, Ulla ^a   Jumaa, Pauline ^b   Bener, Abdulbari ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b TAWAM HOSPITAL   (United Arab Emirates)

Author keywords

Candidemia; Diagnosis; Outcome; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLONY STIMULATING FACTOR; CORTICOSTEROID; FLUCONAZOLE; FLUCYTOSINE; FOLIC ACID ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; BACTEREMIA; CANCER; CANCER CHEMOTHERAPY; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG EFFECT; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTENSIVE CARE UNIT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEWBORN; PREVALENCE; PROGNOSIS; PROPHYLAXIS; RISK; SEPTIC SHOCK; SOLID TUMOR; SURVIVAL; TEACHING HOSPITAL; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED ARAB EMIRATES;

ADOLESCENT; ADULT; AGED; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; UNITED ARAB EMIRATES;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; FUNGI;

EID: 0346655390     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001645337     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention. National nosocomial infection surveillance (NNIS) report, data summary from October 1986-April 1996. Am J Infect Control 1996; 24: 380-388.
2. Norusis MJ. SPSS/PC = For Windows, Base System and Advanced Statistics User's Guide. Windows Version 11.0. Chicago: SPSS, 1998.
3. Cox DR. Regression models and life tables. J Roy Stat Assoc 1972; 29: 187-120.
4. American College of Chest Physicians: Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-875.
5. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-678.
6. Beck-Sague CM, Jarvis WR. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247-1251.
7. Jarvis RW, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29: 19-24.
8. Baran Jr J, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: Prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001; 33: 137-139.
9. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; 35: 19-25.
10. Pfaller MA, Jones RN, Doern GV, et al. International Surveillance of Bloodstream Infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886-1889.
11. Rennert G, Rennert HS, Pitlik S, et al. Epidemiology of candidemia - A nationwide survey in Israel. Infection 2000; 28: 26-29.
12. Colombo AL. Epidemiology and treatment of hematogenous candidiasis: A Brazilian perspective. Braz J Infect Dis 2000; 4: 113-118.
13. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-1128.
14. Ellis ME, Qadri SMH, Spence D, et al. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida species from surveillance cultures. J Antimicrob Chemother 1994; 33: 1223-1228.
15. Pfaller MF, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-751.
16. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
17. Uzun O, Ascioglu S, Anaissie E, et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32: 1713-1717.
18. Marr KA, Seidel K, White TC, et al. Candidemia in allogeneic and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-316.
19. Labro MT. Cefodizime as a biological response modifier: A review of its in-vivo, ex-vivo and in-vitro immunomodulatory properties. J Antimicrob Chemother 1990; 26(Suppl. C): 37-47.
20. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis 1989; 8: 99-104.